Alkermes Plc (ALKS) Stock Price, Quote & News

Company Profile

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders....

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 353 1 772 8000

Website: www.alkermes.com

Address:

Connaught House, 1 Burlington Road Dublin 4, Dublin, Ireland

BillionerOfKing Mar. 10 at 11:44 PM

$ALKS Current Stock Price: $27.74 Contracts to trade: $28.0 ALKS Mar 20 2026 Call Entry: $5.10 Exit: $9.33 ROI: 83% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Otus Mar. 9 at 3:48 PM

$ALKS overreacting to leadership change.

0 · Reply

erevnon Feb. 26 at 5:47 PM

Wells Fargo maintains Alkermes $ALKS at Overweight and raises the price target from $37 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

ZacksResearch Feb. 26 at 4:44 PM

$ALKS beats Q4 — yet the stock drops 7%. What’s the market seeing? 📉 Earnings and revenue both topped estimates, but shares slid after the company announced a CEO transition plan. Strong numbers, leadership change — that combo can create uncertainty. Is this dip a reactionary selloff or a sign of deeper concerns? Full breakdown of the quarter and transition plan 👉 https://www.zacks.com/stock/news/2876085/alkermes-down-despite-q4-earnings-beat-announces-leadership-change?cid=sm-stocktwits-2-2876085-teaser-35317&ADID=SYND_STOCKTWITS_TWEET_2_2876085_TEASER_35317

0 · Reply

ZacksResearch Feb. 26 at 3:44 PM

$ALKS down 7% despite Q4 earnings beat — what's weighing on the stock? 🤔 📉 Total revenues fell 10.6% from the year-ago quarter, with a sharp 43.4% drop in manufacturing and royalty revenues. 📈 However, sales of proprietary products increased 2.5%, driven by strong demand for Lybalvi. Understand the market reaction here 👉 https://www.zacks.com/stock/news/2876085/alkermes-down-despite-q4-earnings-beat-announces-leadership-change?cid=sm-stocktwits-2-2876085-body-35309&ADID=SYND_STOCKTWITS_TWEET_2_2876085_BODY_35309

0 · Reply

d_risk Feb. 25 at 7:11 PM

$ALKS - Alkermes plc - 10K - Updated Risk Factors ALKS adds major new risks from the Avadel deal and LUMRYZ: integration and synergy shortfalls, REMS and DEA/controlled-substance compliance, third‑party manufacturing and quota limits, plus heavy new debt and heightened exposure to U.S. drug pricing and Medicaid/Medicare policy shifts that could hit revenues. #Pharmaceuticals #MergersIntegration #RegulatoryCompliance #DebtRisk #U.S.DrugPricing 🟢 Added 🟠 Removed https://d-risk.ai/ALKS/10-K/2026-02-25

1 · Reply

StocktwitsEarnings Feb. 25 at 12:17 PM

$ALKS Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.30 down -66.67% YoY • Reported revenue of $384.55M down -10.57% YoY • Alkermes plc expects 2026 total revenues between $1.73B and $1.84B, with GAAP Net Loss projected from $115M to $135M, and Adjusted EBITDA between $370M and $410M.

0 · Reply

StockNews_Live Feb. 25 at 11:55 AM

$ALKS Alkermes plc announced that Richard Pops will retire as Chief Executive Officer, effective July 31, 2026. Blair Jackson, current Executive Vice President and Chief Operating Officer, will succeed Pops…

1 · Reply

Estimize Feb. 25 at 11:00 AM

$ALKS reported - EPS and - revenue for Q4. http://www.estimize.com/intro/alks?chart=historical&metric_name=eps&utm_content=ALKS&utm_medium=

0 · Reply

Quantumup Feb. 24 at 2:12 PM

Wolfe Research🏁 $CNTA Outperform/$40, and said, The Next Big Idea in CNS - A High-Conviction Orexin Play; Initiate with OP; $40 PT $ALKS $TAK $HRMY $ESALY Wolfe Research added, While multiple orexin-2 agonists demonstrated strong clinical data in late-stage studies, we believe CNTA's ORX750 would become the best-in-class product and generate >$3B US peak sales ➢ Key upcoming catalysts: Additional Ph2 data for higher doses expected in 1Q26, we expect good data which should move the stock up significantly (+40-50%).

0 · Reply

Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program

Mar 10, 2026, 4:00 PM EDT - 5 days ago

Alkermes to Present at the Stifel 2026 Virtual CNS Forum

Feb 25, 2026, 12:47 PM EST - 18 days ago

Alkermes plc (ALKS) Q4 2025 Earnings Call Transcript

Feb 25, 2026, 7:00 AM EST - 18 days ago

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026

Feb 25, 2026, 6:55 AM EST - 18 days ago

Alkermes plc Announces CEO Succession Plan

Feb 24, 2026, 4:00 PM EST - 19 days ago

Alkermes to Present at the TD Cowen 46th Annual Health Care Conference

Feb 12, 2026, 7:30 AM EST - 4 weeks ago

Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market

AVDL

Feb 11, 2026, 4:00 PM EST - 4 weeks ago

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026

Jan 13, 2026, 4:25 PM EST - 2 months ago

Alkermes plc (ALKS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 8, 2026, 9:16 PM EST - 2 months ago

Alkermes: Avadel Deal And Vibrance-2 Unlock Upside

Jan 6, 2026, 7:00 AM EST - 2 months ago

Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1

Dec 30, 2025, 4:00 PM EST - 2 months ago

Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 12, 2025, 4:38 PM EST - 3 months ago

Avadel Pharmaceuticals Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avadel Pharmaceuticals plc - AVDL

Dec 5, 2025, 7:08 PM EST - 3 months ago

Alkermes plc (ALKS) Presents at Evercore 8th Annual Healthcare Conference Transcript

Nov 25, 2025, 4:00 PM EST - 3 months ago

Alkermes to Participate in Two Upcoming Investor Conferences

Nov 19, 2025, 6:08 AM EST - 4 months ago

Alkermes raises offer for Avadel after Lundbeck bid

AVDL

Nov 19, 2025, 6:00 AM EST - 4 months ago

Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc

AVDL

Nov 17, 2025, 5:37 PM EST - 4 months ago

Alkermes plc (ALKS) Shareholder/Analyst Call Transcript

Nov 14, 2025, 11:37 AM EST - 4 months ago

Lundbeck's Higher Buyout Proposal Challenges Alkermes' Pending $2 Billion Avadel Deal

AVDL

Nov 14, 2025, 9:40 AM EST - 4 months ago

H. Lundbeck Launches Bid for Avadel in Move to Scuttle Alkermes Deal

AVDL

Nov 14, 2025, 8:17 AM EST - 4 months ago

Alkermes reviewing options after Lundbeck makes unsolicited bid for Avadel

AVDL

Nov 14, 2025, 7:45 AM EST - 4 months ago

Alkermes Response to Avadel Announcement

Nov 14, 2025, 5:45 AM EST - 4 months ago

Avadel Receives Unsolicited Proposal from Lundbeck

AVDL

Nov 12, 2025, 12:46 PM EST - 4 months ago

Alkermes Eyes Global Phase 3 Trial After Encouraging Data From Sleep Disorder Study

Nov 12, 2025, 7:35 AM EST - 4 months ago

Alkermes' narcolepsy drug meets main goal in a mid-stage trial

Nov 12, 2025, 7:30 AM EST - 4 months ago

Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2

Nov 5, 2025, 9:00 AM EST - 4 months ago

FORM 8.1(a) & (b) (Opening Position Disclosure)

Nov 3, 2025, 9:58 AM EST - 4 months ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV ALNY AMGN BMY LLY MBX MDGL

Oct 28, 2025, 3:21 PM EDT - 4 months ago

Alkermes plc (ALKS) Q3 2025 Earnings Call Transcript

Oct 28, 2025, 7:00 AM EDT - 4 months ago

Alkermes plc Reports Third Quarter 2025 Financial Results

Oct 22, 2025, 3:18 PM EDT - 5 months ago

Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz

AVDL

Oct 22, 2025, 10:53 AM EDT - 5 months ago

Alkermes plc (ALKS) M&A Call Transcript

Oct 22, 2025, 7:11 AM EDT - 5 months ago

Alkermes to acquire Avadel for up to $2.1 billion

AVDL

Oct 22, 2025, 7:00 AM EDT - 5 months ago

Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc

AVDL

Oct 20, 2025, 4:00 PM EDT - 5 months ago

Alkermes to Report Third Quarter Financial Results on October 28, 2025

Sep 12, 2025, 9:00 AM EDT - 6 months ago

Alkermes Appoints Joshua Reed as Chief Financial Officer

Sep 11, 2025, 7:00 AM EDT - 6 months ago

Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program

Sep 8, 2025, 2:34 PM EDT - 6 months ago

Alkermes Plc (ALKS) World Sleep Congress 2025 (Transcript)

Sep 8, 2025, 3:15 AM EDT - 6 months ago

Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025

Aug 25, 2025, 7:00 AM EDT - 7 months ago

Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025

Jul 30, 2025, 5:08 PM EDT - 8 months ago

Alkermes: A More Than Solid Quarter

Jul 29, 2025, 2:47 PM EDT - 8 months ago

Alkermes plc (ALKS) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 7:00 AM EDT - 8 months ago

Alkermes plc Reports Second Quarter 2025 Financial Results

Jul 21, 2025, 6:00 AM EDT - 8 months ago

Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1

Jul 15, 2025, 4:00 PM EDT - 8 months ago

Alkermes to Report Second Quarter Financial Results on July 29, 2025

Jun 2, 2025, 4:00 PM EDT - 10 months ago

Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Jun 2, 2025, 7:00 AM EDT - 10 months ago

Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences

May 1, 2025, 4:31 PM EDT - 11 months ago

Alkermes: Label Expansion Of LYBALVI With Ongoing Pediatric Trial Possible

May 1, 2025, 11:21 AM EDT - 11 months ago

Alkermes plc (ALKS) Q1 2025 Earnings Call Transcript

May 1, 2025, 7:00 AM EDT - 11 months ago

Alkermes plc Reports First Quarter 2025 Financial Results

BillionerOfKing Mar. 10 at 11:44 PM

0 · Reply

Otus Mar. 9 at 3:48 PM

$ALKS overreacting to leadership change.

0 · Reply

erevnon Feb. 26 at 5:47 PM

Wells Fargo maintains Alkermes $ALKS at Overweight and raises the price target from $37 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

ZacksResearch Feb. 26 at 4:44 PM

0 · Reply

ZacksResearch Feb. 26 at 3:44 PM

0 · Reply

d_risk Feb. 25 at 7:11 PM

1 · Reply

StocktwitsEarnings Feb. 25 at 12:17 PM

0 · Reply

StockNews_Live Feb. 25 at 11:55 AM

1 · Reply

Estimize Feb. 25 at 11:00 AM

$ALKS reported - EPS and - revenue for Q4. http://www.estimize.com/intro/alks?chart=historical&metric_name=eps&utm_content=ALKS&utm_medium=

0 · Reply

Quantumup Feb. 24 at 2:12 PM

0 · Reply

Otus Feb. 21 at 10:42 PM

$ALKS if b of a Analysis gives this a neutral rating and given their history with avadel and jazz, then this is more than likely a strong buy with a price target of 42 plus.

0 · Reply

erevnon Feb. 20 at 11:48 AM

B of A Securities maintains Alkermes $ALKS at Neutral and raises the price target from $33 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

SuperGreenToday Feb. 19 at 12:13 PM

$ALKS Share Price: $32.02 Contract Selected: May 15, 2026 $30 Calls Buy Zone: $4.59 – $5.67 Target Zone: $8.17 – $9.98 Potential Upside: 68% ROI Time to Expiration: 84 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

ZacksResearch Feb. 18 at 2:49 PM

$NVO's Wegovy gets EC nod for higher dose — but is it enough to boost the stock? NVO shares down 9.9% in six months, lagging the industry’s 27.4% growth New 7.2 mg Wegovy dose shows promising weight loss results, yet the stock carries a Zacks Rank #5 (Strong Sell) Some better-ranked stocks are $HRMY, $ALKS, and $CSTL. Opportunity or risk? Full analysis here 👉 https://www.zacks.com/stock/news/2871232/eu-approves-novo-nordisks-higher-dose-wegovy-for-obesity-patients?cid=sm-stocktwits-2-2871232-body-33960&ADID=SYND_STOCKTWITS_TWEET_2_2871232_BODY_33960

0 · Reply

Otus Feb. 17 at 5:08 PM

$ALKS bought several thousand more shares today.

1 · Reply

OfficialStocktwitsUser Feb. 16 at 2:07 PM

$ALKS RSI: 50.29, MACD: 0.9256 Vol: 0.96, MA20: 33.85, MA50: 30.85 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Its_Only_Money_369 Feb. 13 at 11:04 PM

$ALKS $AVDL Can anyone explain why my June and January AVDL options that were OTM have been converted to 2/20/26 Options? I had 17.50 and 20.00 puts and 22.50 calls. They are not tradable but appear as if they can still be exercised. I sold all my 20.00 calls thinking I would loose the positive spread on the buyout. Now I’m questioning if I could have held them and exercised them with cash from shares and recieved 100 CVRs for each contract🧐

0 · Reply

LarryYMB Feb. 13 at 3:07 PM

$AVDL asta la vista, it didn't work fully as expected, will see you at $ALKS , cheers to you all winners, and before I forget, fk you anphony!

2 · Reply

Otus Feb. 12 at 5:07 PM

$ALKS added a few thousand shares today.

0 · Reply

jim22u Feb. 12 at 4:53 PM

$ALKS Back in for 1500 shares. Buying the fear.

0 · Reply

HoHoHoHum Feb. 12 at 1:25 PM

$ALKS Alkermes Plc completes acquisition of Avadel Pharmaceuticals plc (AVDL), accelerating entry into sleep medicine market 48 minutes agoPublished 48 minutes http://agoBriefing.com Augments Alkermes' revenue growth profile and diversifies commercial portfolio with new high potential growth product, LUMRYZ (Sodium Oxybate) for extended-release oral suspension. Expected to be accretive in 2026. Positions the combined organization to accelerate innovation and leadership in development of treatments for sleep disorders and other neurological disorders. Alkermes' financial expectations for 2026 will include certain expenses related to the transaction, including: In the first quarter of 2026, Alkermes will record transaction-related costs of $40 million. Alkermes will record approximately $180 million of LUMRYZ inventory fair value step-up, which will be expensed as cost of goods sold as the inventory is sold in 2026.Alkermes will record approximately $1.5 billion of intellectual property ….

1 · Reply

SuperGreenToday Feb. 11 at 9:03 AM

$ALKS Share Price: $34.73 Contract Selected: May 15, 2026 $35 Calls Buy Zone: $2.15 – $2.66 Target Zone: $3.83 – $4.68 Potential Upside: 68% ROI Time to Expiration: 92 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Market Cap	4.63B
Revenue (ttm)	1.48B
Net Income (ttm)	241.66M
EPS (ttm)	N/A
PE Ratio	18.76
Forward PE	33.71
Profit Margin	16.37%
Debt to Equity Ratio	0.00

Volume	2,896,700
Avg Vol	2,089,334
Day's Range	N/A - N/A
Shares Out	166.65M
Stochastic %K	22%
Beta	0.53
Analysts	Strong Sell
Price Target	$43.94